Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Healthtrust
Citi
Julphar
Fish and Richardson
Mallinckrodt
UBS
Express Scripts
McKinsey
Fuji

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,338,478

« Back to Dashboard

Which drugs does patent 8,338,478 protect, and when does it expire?

Patent 8,338,478 protects TOVIAZ and is included in one NDA.

This patent has fifty-one patent family members in twenty-eight countries.
Summary for Patent: 8,338,478
Title:Derivatives of 3,3-diphenylpropylamines
Abstract: The invention concerns novel derivatives of 3,3-diphenyl-propylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
Inventor(s): Meese; Claus (Monheim, DE), Sparf; Bengt (Trangsund, DE)
Assignee: UCB Pharma GmbH (Monheim, DE)
Application Number:13/161,049
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 8,338,478

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-001 Oct 31, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY ➤ Sign Up
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-002 Oct 31, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,338,478

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98108608May 12, 1998

Non-Orange Book US Patents Family Members for Patent 8,338,478

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,713,464 Derivatives of 3,3-diphenylpropylamines ➤ Sign Up
7,855,230 Derivatives of 3,3-diphenylpropylamines ➤ Sign Up
7,985,772 Derivatives of 3,3-diphenylpropylamines ➤ Sign Up
7,230,030 Derivatives of 3,3-diphenylpropylamines ➤ Sign Up
7,384,980 Derivatives of 3,3-diphenylpropylamines ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,338,478

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 200003319 ➤ Sign Up
Slovakia 286052 ➤ Sign Up
Slovakia 15472000 ➤ Sign Up
Russian Federation 2199525 ➤ Sign Up
Portugal 1077912 ➤ Sign Up
Poland 218882 ➤ Sign Up
Poland 202489 ➤ Sign Up
Poland 195581 ➤ Sign Up
Poland 347823 ➤ Sign Up
New Zealand 507487 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Boehringer Ingelheim
Queensland Health
Teva
Cerilliant
US Army
Accenture
QuintilesIMS
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot